Last reviewed · How we verify
Azithromycin 1gm
Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and halting bacterial growth.
Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and halting bacterial growth. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Acute otitis media.
At a glance
| Generic name | Azithromycin 1gm |
|---|---|
| Also known as | anti chlamydial treatment |
| Sponsor | Ain Shams Maternity Hospital |
| Drug class | Macrolide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Azithromycin is a macrolide antibiotic that binds irreversibly to the bacterial 50S ribosomal subunit, blocking the translocation of peptides and inhibiting protein synthesis. This bacteriostatic action prevents bacterial replication and allows the immune system to clear the infection. It has broad-spectrum activity against many gram-positive and gram-negative bacteria, as well as atypical organisms.
Approved indications
- Community-acquired pneumonia
- Acute bacterial sinusitis
- Acute otitis media
- Pharyngitis/tonsillitis
- Uncomplicated skin and soft tissue infections
- Sexually transmitted infections (Chlamydia trachomatis, Neisseria gonorrhoeae)
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
- Vomiting
- QT prolongation
- Hepatotoxicity
Key clinical trials
- The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial) (PHASE4)
- Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin (PHASE4)
- Ivermectin Versus Standard Treatment in Mild COVID-19 (PHASE3)
- Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus (PHASE3)
- Impact of Antichlamydial Treatment on the Rate of Preeclampsia (PHASE4)
- "Performance of HPV DNA Test in Presence of Co-infection With Common RTIs" (NA)
- PPROM Erythromycin Versus Azithromycin
- Timing of Antibiotic Prophylaxis for Cesarean Deliveries (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azithromycin 1gm CI brief — competitive landscape report
- Azithromycin 1gm updates RSS · CI watch RSS
- Ain Shams Maternity Hospital portfolio CI